Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Retained Earnings (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Retained Earnings for 12 consecutive years, with -$4.6 million as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings rose 99.35% year-over-year to -$4.6 million; the TTM value through Mar 2026 reached -$4.6 million, up 99.35%, while the annual FY2025 figure was -$4.6 million, 99.34% up from the prior year.
  • Retained Earnings hit -$4.6 million in Q1 2026 for Cartesian Therapeutics, roughly flat from -$4.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$4.5 million in Q2 2022 and bottomed at -$709.8 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$250.9 million, with a median of -$4.6 million recorded in 2023.
  • Year-over-year, Retained Earnings crashed 15014.35% in 2025 and then skyrocketed 99.35% in 2026.
  • Cartesian Therapeutics' Retained Earnings stood at -$4.6 million in 2022, then plummeted by 13385.02% to -$614.6 million in 2023, then dropped by 12.6% to -$692.1 million in 2024, then skyrocketed by 99.34% to -$4.6 million in 2025, then decreased by 0.15% to -$4.6 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$4.6 million, -$4.6 million, and -$4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.